36
Participants
Start Date
September 25, 2017
Primary Completion Date
December 24, 2017
Study Completion Date
December 24, 2017
GC4711 30 mg IV
GC4711 will be infused IV as a single dose of 30 mg (3 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump
GC4711 50 mg IV
GC4711 will be infused IV as a single dose of 50 mg (5 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totalling 250 mL, over a 60-minute period using a programmable pump.
GC4419 45 mg IV
GC4419 will be infused IV as a single dose of 45 mg (5 mL GC4419 at 9 mg/mL) in 245 mL normal (0.9%) saline, totalling 250 mL, over a 60-minute period using a programmable pump.
Nucleus Network Limited, Melbourne
Lead Sponsor
Collaborators (1)
Syneos Health
OTHER
Galera Therapeutics, Inc.
INDUSTRY